This is also one of the highest financings in the domestic microbiome industry.
The refills of well-known domestic and foreign investment institutions, such as Legend Capital, Gaorong Capital, 5Y Capital Capital, Primavera Capital Group, Wuyuan Capital, Chunhua HIKE Capital Capital and Tiantu Capital, have indicated that investors are optimistic about Xbiome in the field of micro-ecological pharmaceuticals.
Allegedly, the funds are earmarked for the clinical trials of drugs, IND application projects in the US and China, the R&D of candidate drug lines, and the company’s upgrading process.
Shenzhen Xbiome Biotech Co. Ltd., a leading AI-based microbiome drug development company founded in 2017, is dedicated to developing microbiome therapies such as fecal microbiota transplantation (FMT) and mini-FMT for the alleviation and treatment of intestinal and other related diseases.
With micro-ecological drugs entering the mature stage of transformation, Xbiome will seize this development opportunity and launch a new strategy of 'AI×BT'— integration of AI and BT technologies and talents in depth — thus further improving the conversion efficiency of microecological drugs and building an industry-leading microbial drug asset incubation platform.